What is Section 280E?

Section 280E of the Internal Revenue Code is a federal tax provision enacted in 1982 that prohibits businesses trafficking in Schedule I or Schedule II controlled substances from deducting ordinary business expenses on their federal tax returns. Because cannabis remains classified as a Schedule I controlled substance at the federal level, all plant-touching cannabis companies in the United States are subject to 280E, dramatically increasing their effective tax rates.

Under 280E, cannabis companies can only deduct the cost of goods sold (COGS) from their gross income. All other normal business expenses, including rent, payroll, marketing, insurance, utilities, and administrative costs, are non-deductible. This means that a cannabis company with $10 million in revenue, $5 million in COGS, and $4 million in operating expenses would pay taxes on $5 million (gross profit) rather than $1 million (operating income), resulting in effective tax rates that can exceed 70%.

Section 280E has profound implications for cannabis company financials. It suppresses net income and free cash flow, making it harder for operators to reinvest in their businesses, pay down debt, or return capital to shareholders. Some companies structure their operations to maximize COGS allocations within the bounds of the law, and vertically integrated operators may have more flexibility to classify costs as production-related. However, aggressive 280E tax strategies carry audit risk.

The potential rescheduling of cannabis to Schedule III would eliminate the 280E burden, as the provision only applies to Schedule I and II substances. This is why rescheduling discussions have such an outsized impact on cannabis stock prices. Analysts estimate that eliminating 280E could improve net income for major MSOs by hundreds of millions of dollars annually, making it the single largest potential catalyst for the sector.

Section 280E is arguably the single most impactful issue facing US cannabis companies today. It creates an artificial profitability ceiling that makes it nearly impossible for plant-touching operators to report strong net income or generate substantial free cash flow, regardless of how well they manage their operations. This tax burden puts US cannabis companies at a significant disadvantage compared to Canadian LPs, which are not subject to 280E.

The potential elimination of 280E through cannabis rescheduling to Schedule III is the most significant catalyst on the horizon for US MSOs. Industry analysts estimate that 280E repeal could immediately boost EBITDA margins by 20-30 percentage points for major operators. This potential windfall is already partially priced into cannabis stocks, which is why rescheduling news has such an outsized impact on the sector.